The read at a glance
Computed from the FY2024 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -50.16 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -1.07 — flag raised, worth a closer lookWatch
- Earnings quality 38/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2024, as Clearside Biomedical, Inc. reports it. History and quarterly detail are in the app.
- License$1.7M
- Training Materials And Clinical Supplies$900K
- Product And Service Other$700K
Leadership changes
From Clearside Biomedical, Inc.'s own filings, the day they're filed.
- Clay B. Thorp · Chairperson · appointmenteff. 2025-08-13
- Anthony Gibney · Chairperson · departureeff. 2025-08-11
- Anthony S. Gibney · director · appointmenteff. 2024-04-15
Latest filings
- 8-K · Company announcement2025-12-29
- 8-K · Company announcement2025-12-08
- 8-K · Company announcement2025-11-25
- 10-Q · Quarterly report2025-11-14
- 8-K · Company announcement2025-10-07
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Clearside Biomedical, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Clearside Biomedical, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.